More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients
- PMID: 34672372
- DOI: 10.1002/jso.26723
More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients
Abstract
Background: We evaluated the outcome of sentinel lymph node biopsies (SLNB) in patients with thin melanoma before and after the implementation of AJCC 8th edition (AJCC8) and identified predictors of positive sentinel lymph nodes (+SLN).
Methods: Patients diagnosed with T1 melanomas (Breslow thickness ≤1 mm) during 2016-2017 as per AJCC 7th edition (AJCC7) (n = 3414) and 2018-2019 as per AJCC8 (n = 3734) were identified in the Danish Melanoma Database.
Results: More SLNBs were performed in the AJCC8 cohort compared to the AJCC7 (22.2% vs. 16.2%, p < 0.001), with no significant difference in +SLN rates (4.7% vs. 6.7%, p = 0.118). In the AJCC7 + SLN subgroup, no melanomas were ulcerated, 94.6% had mitotic rate (MR) ≥ 1, 67.6% were ≥0.8 mm and 32.4% would be T1a according to AJCC8. In the AJCC8 + SLN subgroup, 10.3% were ulcerated, 74.4% had MR≥ 1, 97.4% were ≥0.8 mm and 23.1% would be T1a according to AJCC7. On multivariable analysis younger age and MR ≥ 1 were significant predictors of +SLN.
Conclusion: More SLNBs were performed in T1 melanomas after transition to AJCC8 without an increase in +SLN rate. None of the AJCC8 T1b criteria were significant predictors of +SLN. We suggest that mitosis and younger age should be considered as indications for SLNB in thin melanoma.
Keywords: cancer staging; lymph node metastasis; mitosis; ulceration.
© 2021 Wiley Periodicals LLC.
Comment in
-
RE: More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients.J Surg Oncol. 2022 Jun;125(8):1343-1344. doi: 10.1002/jso.26775. Epub 2022 Mar 30. J Surg Oncol. 2022. PMID: 35353374 No abstract available.
Similar articles
-
The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.Melanoma Res. 2015 Apr;25(2):157-63. doi: 10.1097/CMR.0000000000000143. Melanoma Res. 2015. PMID: 25647736
-
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy.Melanoma Res. 2022 Dec 1;32(6):469-476. doi: 10.1097/CMR.0000000000000851. Epub 2022 Oct 26. Melanoma Res. 2022. PMID: 36317389
-
Predictors of SLNB in Thin Melanoma: Understanding the Impact of the American Joint Committee on Cancer 8th Edition Staging System.J Am Coll Surg. 2025 Apr 1;240(4):518-527. doi: 10.1097/XCS.0000000000001296. Epub 2025 Mar 17. J Am Coll Surg. 2025. PMID: 39846473
-
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.J Clin Oncol. 2018 Feb 1;36(4):399-413. doi: 10.1200/JCO.2017.75.7724. Epub 2017 Dec 12. J Clin Oncol. 2018. PMID: 29232171
-
Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one.Dermatol Surg. 2011 Aug;37(8):1080-8. doi: 10.1111/j.1524-4725.2011.02015.x. Epub 2011 Jun 2. Dermatol Surg. 2011. PMID: 21635622 Review.
Cited by
-
Advances in melanoma: epidemiology, diagnosis, and prognosis.Front Med (Lausanne). 2023 Nov 22;10:1268479. doi: 10.3389/fmed.2023.1268479. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38076247 Free PMC article. Review.
-
Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis.Int J Dermatol. 2023 Jan;62(1):56-61. doi: 10.1111/ijd.16515. Epub 2022 Nov 28. Int J Dermatol. 2023. PMID: 36440797 Free PMC article.
-
Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort.World J Surg Oncol. 2024 Aug 30;22(1):228. doi: 10.1186/s12957-024-03512-4. World J Surg Oncol. 2024. PMID: 39215342 Free PMC article.
-
A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP.Cancer Med. 2025 Apr;14(7):e70839. doi: 10.1002/cam4.70839. Cancer Med. 2025. PMID: 40165762 Free PMC article.
References
REFERENCES
-
- Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
-
- Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302-313.
-
- Serra-Arbeloa P, Rabines-Juárez ÁO, Álvarez-Ruiz MS, Guillén-Grima F. Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: a cost-effectiveness analysis. Surg Oncol. 2016;25(3):205-211.
-
- Agnese DM, Abdessalam SF, Burak WE, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134(4):542-547.
-
- Helvind NM, Hölmich LR, Smith S, et al. Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: a national database study of 24 059 melanoma cases. JAMA Dermatol. 2015; 151(10):1087-1095.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical